Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14330601 | 0.94 | ADORA3 (0.49) | ADORA3ADORA2AKIF11MAPTGABRA1 | |
| SCHEMBL14330604 | 0.90 | ADORA3 (0.43) | ADORA3ADORA2AKIF11MAPTGABRA1 | |
| SCHEMBL19988646 | 0.78 | NPC1 (0.53) | ADORA3ADORA2AKIF11MAPTGABRA1 | |
| SCHEMBL14329668 | 0.77 | MAPT (0.45) | ADORA2AMAPTGABRA1GABRG2GABRB3 | |
| SCHEMBL21155426 | 0.75 | MAPT (0.56) | ADORA3ADORA2AKIF11MAPTGABRA1 | |
| SCHEMBL19988645 | 0.74 | CDK4 (0.68) | ADORA3ADORA2AKIF11MAPTGABRA1 | |
| SCHEMBL19988541 | 0.74 | GABRA1 (0.48) | ADORA3ADORA2AKIF11MAPTGABRA1 | |
| SCHEMBL14329656 | 0.74 | CCR1 (0.46) | ADORA3ADORA2AKIF11GABRA1GABRG2 | |
| SCHEMBL12396542 | 0.73 | PARP1 (0.55) | ADORA3ADORA2AKIF11MAPTGABRA1 | |
| SCHEMBL30322789 | 0.73 | PARP1 (0.55) | ADORA3ADORA2AKIF11MAPTGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8771844-B2 | Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-07-08 | — | — | US | disclosed |
| US-8771844-B2 | Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-07-08 | — | — | US | disclosed |
| US-20120326135-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-12-27 | — | — | US | disclosed |
| US-20120326135-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120326135-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | DDT, DRD1, HTR3D | ADORA3 3221/4885ADORA2A 1620/4885KIF11 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.